OBJECTIVES: The aim of the study was to determine the relationship between alcohol consumption and liver fibrosis as assessed by aspartate aminotransferase to platelet ratio index (APRI) in HIV-infected adults and to explore the relative contributions of alcohol and hepatitis C virus (HCV) to APRI among HIV/HCV-coinfected adults. METHODS: We performed a cross-sectional analysis of data from an observational clinical cohort. Alcohol consumption was categorized according to National Institute on Alcohol Abuse and Alcoholism guidelines. We defined significant liver disease as APRI>1.5, and used multinomial logistic regression to identify correlates of increased APRI. RESULTS: Among 1358 participants, 10.4% reported hazardous drinking. It was found that 11.6% had APRI>1.5, indicating liver fibrosis. Hazardous drinking was associated with increased APRI [adjusted relative risk ratio (RRR) 2.30; 95% confidence interval (CI) 1.26-4.17]. Other factors associated with increased APRI were male gender, viral hepatitis, and HIV transmission category of injecting drug use. Among coinfected individuals, 18.3% had APRI>1.5, and hazardous drinking was not associated with APRI. Among non-HCV-infected individuals, 5.3% had APRI>1.5 and hazardous drinking was associated with increased APRI (adjusted RRR 3.72; 95% CI 1.40-9.87). CONCLUSIONS: Hazardous drinking is an important modifiable risk factor for liver fibrosis, particularly among non-HCV-infected patients. Clinicians and researchers must address alcohol use as the burden of liver disease increases among HIV-positive individuals.
OBJECTIVES: The aim of the study was to determine the relationship between alcohol consumption and liver fibrosis as assessed by aspartate aminotransferase to platelet ratio index (APRI) in HIV-infected adults and to explore the relative contributions of alcohol and hepatitis C virus (HCV) to APRI among HIV/HCV-coinfected adults. METHODS: We performed a cross-sectional analysis of data from an observational clinical cohort. Alcohol consumption was categorized according to National Institute on Alcohol Abuse and Alcoholism guidelines. We defined significant liver disease as APRI>1.5, and used multinomial logistic regression to identify correlates of increased APRI. RESULTS: Among 1358 participants, 10.4% reported hazardous drinking. It was found that 11.6% had APRI>1.5, indicating liver fibrosis. Hazardous drinking was associated with increased APRI [adjusted relative risk ratio (RRR) 2.30; 95% confidence interval (CI) 1.26-4.17]. Other factors associated with increased APRI were male gender, viral hepatitis, and HIV transmission category of injecting drug use. Among coinfected individuals, 18.3% had APRI>1.5, and hazardous drinking was not associated with APRI. Among non-HCV-infected individuals, 5.3% had APRI>1.5 and hazardous drinking was associated with increased APRI (adjusted RRR 3.72; 95% CI 1.40-9.87). CONCLUSIONS: Hazardous drinking is an important modifiable risk factor for liver fibrosis, particularly among non-HCV-infectedpatients. Clinicians and researchers must address alcohol use as the burden of liver disease increases among HIV-positive individuals.
Authors: J Poniachik; D E Bernstein; K R Reddy; L J Jeffers; M E Coelho-Little; F Civantos; E R Schiff Journal: Gastrointest Endosc Date: 1996-06 Impact factor: 9.427
Authors: Joseph Conigliaro; Adam J Gordon; Kathleen A McGinnis; Linda Rabeneck; Amy C Justice Journal: J Acquir Immune Defic Syndr Date: 2003-08-01 Impact factor: 3.731
Authors: Anita Palepu; Mark W Tyndall; Kathy Li; Benita Yip; Michael V O'Shaughnessy; Martin T Schechter; Julio S G Montaner; Robert S Hogg Journal: J Urban Health Date: 2003-12 Impact factor: 3.671
Authors: Christopher W Kahler; Tao Liu; Patricia A Cioe; Vaughn Bryant; Megan M Pinkston; Erna M Kojic; Nur Onen; Jason V Baker; John Hammer; John T Brooks; Pragna Patel Journal: AIDS Behav Date: 2017-07
Authors: Joseph K Lim; Janet P Tate; Shawn L Fultz; Joseph L Goulet; Joseph Conigliaro; Kendall J Bryant; Adam J Gordon; Cynthia Gibert; David Rimland; Matthew Bidwell Goetz; Marina B Klein; David A Fiellin; Amy C Justice; Vincent Lo Re Journal: Clin Infect Dis Date: 2014-02-25 Impact factor: 9.079
Authors: Christopher W Kahler; David W Pantalone; Nadine R Mastroleo; Tao Liu; Gerald Bove; Bharat Ramratnam; Peter M Monti; Kenneth H Mayer Journal: J Consult Clin Psychol Date: 2018-08
Authors: H Nina Kim; Robin Nance; Stephen Van Rompaey; Joseph C Delaney; Heidi M Crane; Edward R Cachay; Elvin Geng; Stephen L Boswell; Benigno Rodriguez; Joseph J Eron; Michael Saag; Richard D Moore; Mari M Kitahata Journal: J Acquir Immune Defic Syndr Date: 2016-08-01 Impact factor: 3.731
Authors: Daniel Fuster; Judith I Tsui; Debbie M Cheng; Emily K Quinn; Kaku A Armah; David Nunes; Matthew S Freiberg; Jeffrey H Samet Journal: AIDS Res Hum Retroviruses Date: 2013-05-17 Impact factor: 2.205